Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Elecoglipron

MARKETED

oral non-peptide small-molecule GLP-1 receptor agonist

1
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 0Very low evidence 1

Elecoglipron is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Elecoglipron MARKETED
Weight change Decrease
Very low evidence

Oral non-peptide GLP-1RA (ECC5004/AZD5004; INN elecoglipron), discovered by Eccogene, licensed to AstraZeneca. US phase 1 reported clinically meaningful weight...

Eccogene/AstraZeneca press (license Nov 2023; phase 1b topline Feb 2026) Source
Full findingOral non-peptide GLP-1RA (ECC5004/AZD5004; INN elecoglipron), discovered by Eccogene, licensed to AstraZeneca. US phase 1 reported clinically meaningful weight reductions regardless of T2D status plus glycaemic improvements in T2D. Eccogene reported positive topline phase 1b (China, Feb 2026). Advanced to phase 2b: VISTA (obesity), SOLSTICE (T2D).
PopulationPhase 1 (US) and phase 1b (China) in adults with obesity/overweight +/- T2D; phase 2b VISTA/SOLSTICE ongoing
Fundingindustry (company press release on own pipeline)
Scope limitsno outcome data yet (ongoing)
Comparatorsplacebo